ACRS ▼ -18.4% - Aclaris Therapeutics, Inc. $ACRS Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis - The ADMIRATION Trial Did Not Achieve its Primary Endpoint 16-NOV-2026 05:18 AM ET